The Development of a Novel Nanobody Therapeutic for SARS-CoV-2

Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a novel series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Gang, Gallant, Joseph P., Massey, Christopher, Shi, Ke, Tai, Wanbo, Zheng, Jian, Odle, Abby E., Vickers, Molly A., Shang, Jian, Wan, Yushun, Drelich, Aleksandra, Kempaiah, Kempaiah R., Tat, Vivian, Perlman, Stanley, Du, Lanying, Tseng, Chien-Te, Aihara, Hideki, LeBeau, Aaron M., Li, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685322/
https://www.ncbi.nlm.nih.gov/pubmed/33236012
http://dx.doi.org/10.1101/2020.11.17.386532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685322/
https://www.ncbi.nlm.nih.gov/pubmed/33236012
http://dx.doi.org/10.1101/2020.11.17.386532

Ejemplares similares